

PEPTIDE

# Retatrutide

Triple agonist at GLP-1, GIP, and glucagon receptors; Phase 2 demonstrated up to 24% body weight reduction at 48 weeks.

BIOGATE · GREEN POSTERIOR 82.3% MW 4731.5 39AA

SEQUENCE

YXQGTFTSDYSIYLDKQAAAXEFVNWLLAGGPSSGAPPPS

Modifications: Aib<sup>2</sup>; Aib<sup>13</sup>; Glu-C20 lipid sidechain; amidated C-terminus

## PDA-V1 chain of custody

Outer hash

151-  
ba431141ba29e131ba10b121b9f78191baa7d181ba8ea171ba75716

Merkle root

058-  
d5a7a068d5c0d038d5754048d58e7018d542e028d55c1ff8d5108008d529b

Inputs

97-  
c8e1b196c8e01e95c8de8b94c8dcf89bc8e7fd9ac8e66a99c8e4d79

TEE attestation

8-  
fbc1c890bcd35b91bcd4ee92bcd68193bcd81494bcd9a795bcd3a96bcd-ccd

## Living Outcome Oracle

$\pm$ 63.7	$\sigma$ =13.8	<b>P(success) = 82.3%</b>	95% CI [70.3%, 94.3%]
------------	----------------	---------------------------	-----------------------

## Seven-rule export gate

7 / 7 rules satisfied · audience: researcher · Full attestation set, raw posteriors, all hashes

- Grade A or B citation present on the core claim
- BioGate verdict is GREEN or AMBER (RED/BLACK refused)
- Jurisdiction permits the audience-appropriate use
- RWE summary attached when claim depends on outcome data
- Prediction-outcome pairs disclosed when posterior cited
- No human-use claim beyond cited indications
- COA registry lookup available for any synthesis claim

## Citations

GRADE A 2023 · N Engl J Med

## Triple-Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2)

Jastreboff AM et al.

DOI 10.1056/NEJMoa2301972